Dr. Bazhenova is a Clinical Professor of Medicine at UC San Diego Moores Cancer Center, Lung Cancer Unit Leader and a Director of the Hematology Oncology training program. Dr. Bazhenova’s clinical practice and research concentrate on lung cancer. Dr. Bazhenova has vast experience in clinical trial management, design and implementation.  She serves a vice chair of UC San Diego Protocol Review and Monitoring committee. Dr. Bazhenova is a member of Alliance Respiratory Committee. She is a recipient of NCI Clinical Trial Leadership Award, San Diego Best Doctors awards and Women Who Mean Business Award. Her main research interest is drug development. Dr. Bazhenova completed her M.D. at Nizhny Novgorod State Medical Academy in Nizhny Novgorod, Russia. She graduated from Internal medicine residency at University of California Los Angeles/ West Los Angeles VA medical center and then completed a fellowship in Hematology-Oncology at Scripps-Green Hospital in La Jolla in 2005 and has been in practice at NCI designated UC San Diego Moores Cancer Center since 2005.

Joshua Bauml is an Assistant Professor fo Medicine at the Perelman School of Medicine at the University of Pennsylvania. His clinical and research interests focus on improving outcomes for patients with lung and head and neck cancers using translational research.

Dr. Mark Awad is an Assistant Professor of Medicine at Harvard Medical School and Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute. He received his undergraduate degree from Harvard University and his MD and PhD degrees from the Johns Hopkins School of Medicine. He completed his residency and chief residency at the Massachusetts General Hospital, and his medical oncology fellowship at the Dana-Farber Cancer Institute before joining the Dana-Farber faculty in 2014. His translational research focus is on identifying biomarkers of response and resistance to targeted therapies and immunotherapies in lung cancer. He is a recipient of the 2015 Young Investigator Award from the American Society of Clinical Oncology (ASCO), the 2015 Young Investigator Award from the International Association for the Society of Lung Cancer (IASLC), the 2017 Career Development Award from the Conquer Cancer Foundation of ASCO, and the 2018 ALK Positive/LUNGevity Transformational Research Award.

Kathryn C. Arbour is a thoracic medical oncologist with a clinical and translational research focus on developing immunotherapies and targeted therapies for patients with KRAS mutant non-small cell lung cancer. Dr. Arbour is currently an Assistant Professor at Memorial Sloan Kettering Cancer Center where she joined the faculty after completing her fellowship at Memorial. Her clinical research is focused on improvements in immunotherapy for lung cancer and specifically focused on patients with KRAS mutant lung cancer. Her clinical trial focus is concentrated on developing effective therapies for KRAS mutant NSCLC in patients with both G12C and non-G12C molecular subtypes. She serves as both a clinical investigator overseeing and developing clinical trials as well as a translational researcher identifying potential patterns of primary and acquired resistance to both immunotherapy and targeted therapies.

Dr. Anagnostou is a translational lung cancer investigator who is focusing on understanding the molecular mechanisms of response and resistance to immunotherapy and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients treated with immunotherapy. Dr. Anagnostou is an Assistant Professor of Oncology in the Sidney Kimmel Cancer Center at Johns Hopkins. She graduated from National and Kapodistrian University of Athens, Greece and received a PhD in cancer biology from the same institution. Dr. Anagnostou completed her internal medicine residency at Yale-New Haven Hospital and subsequently trained in Medical Oncology at Johns Hopkins. Her main research focus is studying tumor evolution under the selective pressure of immune targeted agents and she has discovered novel mechanisms of acquired resistance to immune checkpoint blockade related to the evolving neoantigen landscape in resistant tumors. Dr. Anagnostou is developing liquid molecular assays that capture the dynamics of response and may more accurately predict emergence of resistance to immunotherapy. Her long term goal is to incorporate immunogenomic biomarkers in immuno-oncology clinical trial design as well as standard of care.

Dr. Dara Aisner is a board-certified certified Anatomic and Molecular Genetic Pathologist. She is an Associate Professor of Pathology at the University of Colorado School of Medicine in Denver, Colorado and a member of the University of Colorado Comprehensive Cancer Center. She is also board certified in Clinical Informatics. She is the Director of the Colorado Molecular Correlates Laboratory within the Department of Pathology. The laboratory provides CLIA level clinical services in the evaluation of patient tumor specimens for personalized medicine approaches. She is a member of numerous oncology pathology and guidelines committees including the CAP/AMP/IASLC Guidelines for Biomarker Testing in Non-Small Cell Lung Cancer, among others.

Dr. Aggarwal specializes in the management of patients with lung and head and neck cancer. Her clinical research focus is on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of targeted immunotherapy approaches including cellular therapy and CAR-T for solid tumors.

Alex A. Adjei is a Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo College of Medicine, in Rochester, MN. He oversees oncology drug development as well as lung cancer research and treatment across all 3 Mayo Clinic sites, and is co-Leader of the Developmental Therapeutics program at Mayo Cancer Center. Dr. Adjei has served on a number of US National Cancer Institute (NCI) committees. From 2007 to 2013, he was Chair of the NIH Study Section NCRR Clinical Research Review Committee, reviewing CTSAs. From 2010 – 2014, he was a Member of the Clinical Oncology Study Section (CONC), and from 2013-2017, he was a member of NCI IRG Subcommittee A, reviewing Cancer Centers. He is currently co-chair of the Thoracic Malignancies Steering Committee of NCI. He has served on various committees of professional societies. He was the President of the Minorities in Cancer Research Council of AACR and a member of the Board of Directors of IASLC and is currently Faculty Coordinator for Developmental Therapeutics and member of the Gender Medicine Task Force of ESMO.  Dr Adjei is serving on the Committee on Diagnosing and Treating Adult Cancers of the US National Academies of Sciences, Engineering and Medicine, tasked with providing a report on this topic to the US government (Social Security Administration). He is the Editor-in-Chief of the Journal of Thoracic Oncology and JTO Clinical and Research Report.

Dr. Adjei’s research is focused on experimental therapeutics and clinical drug development. He received the first American Society of Clinical Oncology Drug Development Research Professorship 2012-2017, in recognition of his mentorship and his work in cancer drug development. He also received the inaugural IASLC Adi  F. Gazdar Merit Award for Distinguished Service in Lung Cancer, in 2020. He has authored 290 publications dealing primarily with preclinical pharmacology and phase I trials as well as novel therapies for lung cancer.

Tiannan Guo received training of clinical medicine in Tongji Medical College, Huazhong University of Science and Technology (1999-2006), and biology in Wuhan University (2001-2005), before he moved to Singapore for PhD training in cancer proteomics in the laboratories of Dr. Newman Sze in Nanyang Technological University and Dr.Oi Lian Kon in National Cancer Centre Singapore (2008-2012). In 2012, Tiannan started his postdoctoral training in the laboratory of Dr. Ruedi Aebersold in ETH Zurich. In March 2017, Tiannan relocated to ProCan, Children’s Medical Research Institute, The University of Sydney as the Scientific Director. Since August 2017, he became a Tenure Track Assistant Professor in Westlake University, Hangzhou, China. The Guo lab (www.guomics.com) focuses on advancing proteomics technologies for clinical cohort studies.

Purpose
ICS is a conference and association management company.  We are contracted by associations to provide secretariat support for associations and full planning of internationally based conferences.

The purpose of this Privacy Statement is to inform you of the types of personal data International Conference Services Ltd. or ICS subsidiaries (ICS) collects, uses, stores or transfers and why.

Personal Data
Personal data is any information that can be used to identify you, such as your name, email, title, phone number, profession.

What information does ICS collect and why?
ICS collects personal information necessary for the management of associations, conferences and events. The most common types of information that we collect include:names, email addresses, IP addresses, other contact details, profession, qualifications, survey responses, dietary requirements, photos, credit card information, tax information, copies of Passport or ID, quotes, etc.

The information is used to process your registration, take payment, manage your flights and/or accommodation, manage flight bookings, organize meals with the appropriate supplies of food for various dietary requirements, communicate with you about other ancillary events, gain feedback, provide reports to the conference host and to inform you of future conferences.

 Legal basis for processing any personal data

1. To meet ICS’ contractual obligations:
   1. To facilitate and process transactions that take place on our websites, such as when you register for a conference;
   2. To process your membership and give you access to your membership entitlements.
2. To meet the legitimate interests of you and our third parties:
   1. To invite you to a conference hosted by an association which you have expressed interest in;
   2. To ensure you are not omitted from receiving information about specialist events.
3. When you give us consent:
   1. Publishing your name in the delegate list on the website and in the program book;
   2. Sharing your personal information with exhibitor and sponsors of the conference.
4. For the purpose which may be required by law.
5. For the purpose of responding to requests by government, a court of law, or law enforcement authorities conducting an investigation. 

How does ICS collect personal information?
ICS collects personal information directly when you provide it to us.

ICS collects personal information when you provide it to us when you register for an event, subscribe to a newsletter, email list, visit our websites, submit feedback, enter a contest, fill out a survey, or send us a communication. 

What information is collected from third parties?
Conference host organizations may share membership lists and previous congress delegate lists with ICS to allow ICS to inform you of the upcoming conferences.

Who has access to your information and to whom is it disclosed?
We may disclose personal data to the following parties:

1. ICS Group companies;
2. Host organizations;
3. Contractors – who support ICS in our provision of services;
4. Payment processors – to allow payment to be made;
5. Hotels and Travel agencies – to book your accommodation and/or flights;
6. Abstract handling specialists – to manage the abstract submission and review process;
7. Marketing software – to provide you with information about the conference and association;
8. Exhibitors and sponsors – to whom you specifically consent to share your data with.

We do not share your information between clients.  For example, if you sign up for a conference hosted by one association, we would not share your information with other clients organizing other conferences, even if the subject matter was similar.

Where do we transfer and store your personal information?
ICS has offices in Canada, the United States, Austria, and the United Kingdom and so your data will be processed in these countries.  We may disclose your information to recipients outside of where we have offices such as to the country where the conference takes place, or where our contractors reside such as Spain, France or Australia.  We are careful to work with third parties who maintain appropriate standards of data security compliance.

 How do we keep your personal information secure?
We store personal information on secure servers that are managed by us and our service providers, and sometimes hard copy files that are kept in a secure location in Canada, US and the UK.  Personal information that we store or transmit is protected by access controls, such as username and passwords, access granted to only those with a need to know and encryption where possible.

What are your Marketing options?
Where we have your consent to do so (e.g. if you have subscribed to one of our e-mail lists, registered for one of our conferences, or have indicated that you are interested in receiving information from us), we send you marketing communications by email about events that you have previously expressed an interest in. You can ‘opt-out’ of such communications if you would prefer not to receive them in the future by using the “unsubscribe” facility provided in the communication itself.

You also have choices about cookies, as described below. By modifying your browser preferences, you have the choice to accept all cookies, to be notified when a cookie is set, or to reject all cookies. If you choose to reject cookies some parts of our Sites may not work properly in your case.

What are Cookies?
For more information about cookies, see http://www.allaboutcookies.org.

As you browse our website, advertising cookies will be placed on your computer so that we can understand what you are interested in. Our display advertising partner then enables us to present you with advertising on other sites based on your previous interaction with www.wclc2019.iaslc.org. The techniques our partners employ do not collect personal information such as your name, email address, postal address, or telephone number, nor do we share this information directly with them. You can visit this page to opt out of future targeted advertising.

If you’re logged into your account, some of this information could be associated with your account. We’re talking about the following kinds of details:

your IP address or proxy server IP address;

the domain name you requested;

the name of your internet service provider is sometimes captured depending on the configuration of your ISP connection;

the date and time of your visit to the website;

the length of your session;

the pages which you have accessed;

the number of times you access our site within any month;

the file URL you look at and information relating to it;

the website which referred you to our Sites; and

the operating system which your computer uses.

Occasionally, we will use third party advertising companies to serve ads based on prior visits to our websites.  For example, if you visit our websites, you may later see an ad for our events when you visit a different Site.

What if you have previously shared information with others?
If you make your personal information available to other people, we can’t control or accept responsibility for the way they will use or manage that data. There are lots of ways that you can find yourself providing information to other people, like when you post a public message on a forum thread, share information via social media, or make contact with another user (such as a third party Author) whether via our Sites or directly via email. Before making your information publicly available or giving your information to anyone else, think carefully. If giving information to another user via our Sites, ask them how they will handle your information. If you’re sharing information via another website, check the privacy policy for that site to understand its information management practices as this privacy policy will not apply.

Consent
Through agreeing to this privacy notice you are consenting to ICS processing your personal data for the purposes outlined. You can withdraw consent at any time by selecting “unsubscribe” to any emails that you receive from us, or by emailing This email address is being protected from spambots. You need JavaScript enabled to view it.

 How long does ICS keep your data?
ICS will retain your personal information for as long as is necessary to provide the services to you, and to comply with our legal obligations. We retain your information generally until the next cycle of conference, so that we are able to inform you of its occurrence.  If you no longer want to hear from us you can use the unsubscribe mechanism at the bottom of any marketing email.  You may also request a listing of personal data held or for that data to be edited, or erased by emailing ICS’ privacy officer at the contact details below. 

Your rights as a data subject
At any point whilst ICS is in possession of or processing your personal data, all data subjects have the following rights:

• Right of access – you have the right to request a copy of the information that we hold about you.
• Right of rectification – you have a right to correct data that we hold about you that is inaccurate or incomplete.
• Right to be forgotten – in certain circumstances you can ask for the data we hold about you to be erased from our records.
• Right to restriction of processing – where certain conditions apply you have a right to restrict the processing.
• Right of portability – you have the right to have the data we hold about you transferred to another organization.
• Right to object – you have the right to object to certain types of processing such as direct marketing.
• Right to object to automated processing, including profiling – you also have the right not to be subject to the legal effects of automated processing or profiling.

If ICS refuses your request under rights of access, we will provide you with a reason as to why, which you have the right to legally challenge.

ICS at your request can confirm what information it holds about you and how it is processed.

To access what personal data is held, identification will be required
ICS will accept the following forms of ID when information on your personal data is requested: a copy of your national ID card, driver’s license, passport, birth certificate and a utility bill not older than three months. A minimum of one piece of photographic ID listed above and a supporting document is required. If ICS is dissatisfied with the quality, further information may be sought before personal data can be released.

All requests should be made to This email address is being protected from spambots. You need JavaScript enabled to view it..

Cancellation Policy
In the unlikely event that the Conference is cancelled, travel and accommodation costs will not be refunded.

Contact
If you wish to make a compliant about how your personal data is being processed by ICS or its partners, you have the right to complain to ICS’ privacy officer at This email address is being protected from spambots. You need JavaScript enabled to view it.